Form 4: Serina Therapeutics CSO Sells Shares After Option Exercise
Insider Transaction Report
Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, exercised stock options and immediately sold 4,100 shares of common stock for a profit.
Summary
- Randall Moreadith, Chief Scientific Officer of Serina Therapeutics, Inc. (SER), reported a transaction involving the exercise of stock options and subsequent sale of common stock.
- On December 23, 2025, Mr. Moreadith acquired 4,100 shares of common stock by exercising stock options at a price of $0.06 per share.
- Concurrently, Mr. Moreadith disposed of 4,100 shares of common stock at a price of $2.60 per share.
- The transactions were conducted pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.
- Following these transactions, Mr. Moreadith beneficially owns 0 shares of direct common stock and 352,186 derivative securities (stock options).
Sentiment
Score: 4
Explanation: The sentiment is neutral to slightly negative. While the officer realized a profit, the sale of shares by an insider, even under a 10b5-1 plan, can sometimes be perceived negatively by the market, though it's a routine part of compensation management.
Positives
- The Chief Scientific Officer realized a profit from exercising stock options at $0.06 and selling the shares at $2.60, indicating a significant gain per share.
- The transaction was executed under a Rule 10b5-1 plan, suggesting a pre-scheduled and transparent insider trading activity.
Negatives
- The Chief Scientific Officer sold 4,100 shares of common stock, reducing his direct ownership of the company's equity.
Industry Context
Insider transactions, such as option exercises and subsequent share sales, are common occurrences in publicly traded companies, particularly when executives manage their equity compensation and liquidity needs. The use of a Rule 10b5-1 plan indicates a pre-arranged transaction, which is a standard practice to avoid accusations of trading on material non-public information.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Plan Disclosure | The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). | 12/23/2025 | This indicates a pre-planned transaction, which enhances transparency and reduces the perception of opportunistic trading based on non-public information. It aligns with good corporate governance practices regarding insider trading. |
Stakeholder Impact
- Shareholders may interpret the sale of shares by a Chief Scientific Officer as a signal, though the pre-planned nature via a 10b5-1 plan mitigates potential negative implications.
- The transaction demonstrates the executive's ability to monetize vested equity compensation.
Key Dates
| Date | Description |
|---|---|
| 12/23/2025 | Date of earliest transaction, involving both the exercise of stock options and the sale of common stock. |
| 12/24/2025 | Signature date of the reporting person. |
| 05/06/2031 | Expiration date of the stock options. |
Keywords
Serina Therapeutics, SER, Form 4, Insider Trading, Stock Options, Share Sale, Randall Moreadith, Chief Scientific Officer, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.